Skip to main content

Shacham Sharon's Form 4 filing

Karyopharm Therapeutics Inc. (KPTI) · filed Feb 22, 2022

Accession no.
0001209191-22-011639
Filed
Feb 22, 2022
Trade date
Feb 17, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market sales total $220.2K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shacham SharonCIK 0001588438Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 17, 2022Common StockSSaleDisposed−9,088$12.12F2−$110,146.56904,357DirectDuplicate filing
Feb 17, 2022Common StockSSaleDisposed−9,079$12.12F4−$110,037.48698,983IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

Referenced by the price of 1 transaction in Table I.

F4

The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)